Skip to main content
. 2021 Feb 16;7(3):624–635. doi: 10.1021/acsinfecdis.0c00822

Figure 2.

Figure 2

β-GlcNAc-modified WTA is sufficient to confer langerin binding. (A) Schematic overview of the synthetic WTA structures and in vitro glycosylation by recombinant TarS, TarP, or TarM. (B) Binding of recombinant human langerin-FITC (0.4–25 μg/mL) to RboP hexamers alone (RboP backbone) or after in vitro glycosylation by TarS, TarP, or TarM. (C) Binding of recombinant human langerin-FITC (0.4–25 μg/mL) to RboP dodecamers alone (RboP backbone) or after in vitro glycosylation similar to RboP hexamers. Binding to β-GlcNAc WTA was assessed in the absence and presence of EGTA (10 mM). Data for panel B and C are shown as fluorescence signal + SEM of three independent experiments and were compared with the negative control (buffer). *p < 0.05, ****p < 0.0001.